Xspray Pharma Overview

  • Founded
  • 2003
Founded
  • Status
  • Public
  • Employees
  • 22
Employees
  • Stock Symbol
  • XSPRAY
Stock Symbol
  • Share Price
  • $7.13
  • (As of Monday Closing)

Xspray Pharma General Information

Description

XSpray Pharma AB is a product development company with several product candidates in clinical development. It develops, sells and licenses generic versions of marketed cancer drugs, protein kinase inhibitors. The company primarily develops protein kinase inhibitors (PKI) for targeted cancer treatment.

Contact Information

Formerly Known As
CENS Delivery
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
STO
Primary Office
  • Råsundavägen 12
  • 169 67 Solna
  • Sweden
+46 08-730 00 00

Xspray Pharma Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Xspray Pharma Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$7.13 $7.26 $6.58 - $18.99 $150M 20.7M 28K -$0.37

Xspray Pharma Financials Summary

In Thousands,
USD
TTM 30-Sep-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 251,760 434,370 136,266 100,325
Revenue 0 0 0 32
EBITDA (6,247) (4,962) (4,415) (2,205)
Net Income (7,004) (5,684) (4,839) (2,655)
Total Assets 64,350 73,790 42,854 35,078
Total Debt 423 592 570 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Xspray Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Xspray Pharma‘s full profile, request access.

Request a free trial

Xspray Pharma Patents

Xspray Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-10894018-B1 Rapidly disintegrating solid oral dosage forms containing dasatinib Active 17-May-2019 0000000000
US-10874613-B1 Rapidly disintegrating solid oral dosage forms containing dasatinib Active 17-May-2019 0000000000
US-10894017-B1 Rapidly disintegrating solid oral dosage forms containing dasatinib Active 17-May-2019 0000000000
US-10799459-B1 Rapidly disintegrating solid oral dosage forms containing dasatinib Active 17-May-2019 0000000000
US-10874614-B1 Rapidly disintegrating solid oral dosage forms containing dasatinib Active 17-May-2019 A61K31/506
To view Xspray Pharma’s complete patent history, request access »

Xspray Pharma Executive Team (5)

Name Title Board Seat Contact Info
Per Andersson Ph.D Chief Executive Officer
Kerstin Hasselgren Chief Financial Officer
Mustafa Demirbüker Ph.D Science Director & Co-Founder
Gérald Jesson Director, Process Development
You’re viewing 4 of 5 executive team members. Get the full list »

Xspray Pharma Board Members (9)

Name Representing Role Since
Carl-Johan Spak Ph.D Recipharm Board Member 000 0000
Hakan Nykvist Xspray Pharma Co-Founder & Board Member 000 0000
Maris Hartmanis Ph.D Xspray Pharma Board Member 000 0000
You’re viewing 3 of 9 board members. Get the full list »

Xspray Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Xspray Pharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Xspray Pharma‘s full profile, request access.

Request a free trial